COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01361841
Recruitment Status : Unknown
Verified December 2010 by Centre de recherche du Centre hospitalier universitaire de Sherbrooke.
Recruitment status was:  Recruiting
First Posted : May 27, 2011
Last Update Posted : May 27, 2011
Information provided by:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Brief Summary:

Intraocular pressure (IOP) is considered to be the main risk factor for progression of glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has changed considerably during the last decades due to the introduction of prostaglandin analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).

There have been several studies to evaluate their effectiveness. The three seem to be equivalent, according to the only study that has compared the molecules. Latanoprost is employed initially, due to its paucity of side effects when compared to the other two analogues. However, if it is not effective, several studies ahve shown that a result is possible using either travoprost or bimatoprost. No study has been conducted to date systematically comparing the three molecules in cases of resistance to latanoprost. In actuality, the investigators patients will receive treatment identical to current practice with the exception of the group continuing with latanoprost. Several studies confirm the benefit of changing prostaglandin analogues if the first has not signficantly decreased the IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects)

The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost and travoprost in their IOP-lowering capacity in patients who do not initially respond to latanoprost.

Condition or disease Intervention/treatment Phase
Ocular Hypertension Primary Glaucoma Drug: Latanoprost, bimatoprost, travoprost Drug: travoprost, latanoprost and bimatoprost Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 141 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma
Study Start Date : January 2009
Estimated Primary Completion Date : January 2012
Estimated Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
ophtalmic solution,
Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
Drug: Latanoprost, bimatoprost, travoprost
topic drops, once a day at bedtime, for years
Other Names:
  • Xalatan
  • Lumigan
  • Travatan

Drug: travoprost, latanoprost and bimatoprost
one drop once a day for life
Other Names:
  • Travatan
  • Xalatan
  • Lumigan

Primary Outcome Measures :
  1. intraocular pressure [ Time Frame: 2 years ]
    A drop of fluorescein sodium and benoxinate hydrochloride, USP (0.25%/0.4%) will be instilled in the patient's eyes, after which baseline IOP will be measured by Goldmann tonometry. The inter-measurement variability is +/- 2mmHg.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients diagnosed with ocular hypertension or primary open-angle glaucoma who have never received treatment.
  • Age 18 or older and able to give informed consent

Exclusion Criteria:

  • Patients with intraocular inflammation of any etiology
  • Patients with advanced glaucoma, defined by severe optic nerve damage and/or visual field deficit.
  • Patients having had intraocular surgery in the last 4 weeks
  • Patients undergoing treatment with ophthalmic solution of any kind
  • Patients unable to give informed consent to participate in the research project,including those suffering from psychiatric illness resulting in impaired judgement
  • Monophthalmia or anophthalmia
  • Pregnant or nursing patients
  • Patients status post ocular surgery, with the exception of cataract extraction surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01361841

Layout table for location information
Canada, Quebec
Centre hospitalier de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Pierre PB Blondeau, MD    1 (819) 346 1110 ext 28008   
Sponsors and Collaborators
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Layout table for investigator information
Principal Investigator: Pierre Blondeau, MD Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Layout table for additonal information
Responsible Party: Centre Hostitalier Universitaire de Sherbrooke, CHUS Identifier: NCT01361841    
Other Study ID Numbers: CHUS-09-184
First Posted: May 27, 2011    Key Record Dates
Last Update Posted: May 27, 2011
Last Verified: December 2010
Keywords provided by Centre de recherche du Centre hospitalier universitaire de Sherbrooke:
non responders
Additional relevant MeSH terms:
Layout table for MeSH terms
Ocular Hypertension
Eye Diseases
Antihypertensive Agents